Current Report Filing (8-k)
May 10 2021 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May
4, 2021
Aditx Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-39336
|
|
82-3204328
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2569 Wyandotte St., Suite 101
Mountain View, CA
|
|
94043
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (909) 488-0844
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
|
ADTX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On May 4, 2021, Aditx Therapeutics, Inc.
(the “Company”) entered into a lease agreement (the “Lease”) with LS Biotech Eight, LLC (the “Landlord”)
to lease approximately 25,000 rentable square feet (the “Premises”) located at 737 N. 5th Street, Richmond, Virginia
23219 (the “Building”).
The initial term of the Lease (the “Initial
Term”) continues from the Commencement Date (as such term is defined in the Lease) for a period of sixty-three (63) months from
the Commencement Date plus, if the Commencement Date is not the first day of the month, the partial month containing the Commencement
Date (the “Initial Term”). The Initial Term may be extended by the Company pursuant to certain terms and conditions set forth
in the Lease.
Base rent for the first year following the Commencement
Date is $25.50 per square foot, which amount is subject to adjustment based upon the Rentable Area (as such term is defined in the Lease)
of the Premises as of the Commencement Date. The Company is required to pay the Landlord a security deposit of $159,375 in connection
with the Lease.
The Lease contains customary provisions allowing
the Landlord to terminate the Lease, for, among other things, if the Company fails to remedy a breach of any of its obligations within
specified time periods, the Company abandons or vacates all or a portion of the Premises or upon bankruptcy or insolvency of the Company.
The foregoing information is a summary of the
agreements involved in the transaction described above, is not complete, and is qualified in its entirety by reference to the full text
of such agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference. Readers should review
such agreement for a complete understanding of the terms and conditions associated with this transaction.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADITX THERAPEUTICS, INC.
|
|
|
|
Date: May 10, 2021
|
By:
|
/s/ Corinne Pankovcin
|
|
|
Corinne Pankovcin
|
|
|
Chief Financial Officer
|
-2-
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024